Christopher Petucci

Christopher Petucci

Auto-generated profile, based on publicly available information

Christopher Petucci

University of Pennsylvania Cardiovascular Institute, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
JHJulie Horton
Julie Horton
MDMichael T. Davidson
Michael T. Davidson
CKClara Kurishima
Clara Kurishima
RVRick B. Vega
Rick B. Vega
JPJeffery C. Powers
Jeffery C. Powers
DKDaniel P. Kelly
Daniel P. Kelly
Evidence has emerged that the failing heart increases utilization of ketone bodies. We sought to determine whether this fuel shift is adaptive. Mice rendered incapable of oxidizing the ketone body 3-hydroxybutyrate (3OHB) in the heart exhibited worsened heart failure in response to fasting or a pressure overload/ischemic insult compared with WT controls. Increased delivery of 3OHB ameliorated pathologic cardiac remodeling and dysfunction in mice and in a canine pacing model of progressive heart failure. 3OHB was shown to enhance bioenergetic thermodynamics of isolated mitochondria in the context of limiting levels of fatty acids. These results indicate that the heart utilizes 3OHB as a metabolic stress defense and suggest that strategies aimed at increasing ketone delivery to the heart could prove useful in the treatment of heart failure.

11 May 2022 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
MPMichael J. Previs
Michael J. Previs
TOThomas S O'Leary
Thomas S O'Leary
MMMichael P. Morley
Michael P. Morley
BPBradley M. Palmer
Bradley M. Palmer
MLMartin LeWinter
Martin LeWinter
SDSharlene M. Day
Sharlene M. Day
Background: Defects in energetics are thought to be central to the pathophysiology of hypertrophic cardiomyopathy (HCM); yet, the determinants of ATP availability are not known. The purpose of this study is to ascertain the nature and extent of metabolic reprogramming in human HCM, and its potential impact on contractile function. Methods: We conducted proteomic and targeted, quantitative metabolomic analyses on heart tissue from patients with HCM and from nonfailing control human hearts. Results: In the proteomic analysis, the greatest differences observed in HCM samples compared with controls were increased abundances of extracellular matrix and intermediate filament proteins and decreased abundances of muscle creatine kinase and mitochondrial proteins involved in fatty acid oxidation. These differences in protein abundance were coupled with marked reductions in acyl carnitines, byproducts of fatty acid oxidation, in HCM samples. Conversely, the ketone body 3-hydroxybutyrate, branched chain amino acids, and their breakdown products, were all significantly increased in HCM hearts. ATP content, phosphocreatine, nicotinamide adenine dinucleotide and its phosphate derivatives, NADP and NADPH, and acetyl CoA were also severely reduced in HCM compared with control hearts. Functional assays performed on human skinned myocardial fibers demonstrated that the magnitude of observed reduction in ATP content in the HCM samples would be expected to decrease the rate of cross-bridge detachment. Moreover, left atrial size, an indicator of diastolic compliance, was inversely correlated with ATP content in hearts from patients with HCM. Conclusions: HCM hearts display profound deficits in nucleotide availability with markedly reduced capacity for fatty acid oxidation and increases in ketone bodies and branched chain amino acids. These results have important therapeutic implications for the future design of metabolic modulators to treat HCM.

7 March 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
RSRasheed O. Sule
Rasheed O. Sule
PHPo Hu
Po Hu
CSClarissa Shoffler
Clarissa Shoffler
CPChristopher Petucci
Christopher Petucci
BWBenjamin J. Wilkins
Benjamin J. Wilkins
LPLiming Pei
Liming Pei
Background: The Fontan operation is the current standard of care for single‐ventricle congenital heart disease. Almost all patients with Fontan operation develop liver fibrosis at a young age, known as Fontan‐associated liver disease (FALD). The pathogenesis and mechanisms underlying FALD remain little understood, and there are no effective therapies. We aimed to present a comprehensive multiomic analysis of human FALD, revealing the fundamental biology and pathogenesis of FALD. Methods and Results: We recently generated a single‐cell transcriptomic and epigenomic atlas of human FALD using single‐nucleus multiomic RNA sequencing and assay for transposase‐accessible chromatin using sequencing, which uncovered substantial metabolic reprogramming. Here, we applied liquid chromatography–mass spectrometry–based untargeted metabolomics to unveil the metabolomic landscape of human FALD, using liver samples/biopsies from age‐ and sex‐matched donors and patients with FALD (n=12 per group). Results were integrated with liver single‐nucleus multiomic RNA sequencing and assay for transposase‐accessible chromatin using sequencing and serum metabolomics data to present a comprehensive multiomic atlas of FALD.We discovered significant metabolic abnormalities in livers of adolescent patients with Fontan circulation, particularly amino acid metabolism, peroxisomal fatty acid oxidation, cytochrome P450 system, glycolysis, tricarboxylic acid cycle, ketone body metabolism, and bile acid metabolism. Integrated analyses with liver single‐nucleus multiomic RNA sequencing and assay for transposase‐accessible chromatin using sequencing results unveiled potential underlying mechanisms of these metabolic changes. Comparison with serum metabolomics data indicate that liver metabolic reprogramming contributes to circulatory metabolomic changes in FALD. Furthermore, comparison with metabolomics data of human metabolic dysfunction–associated fatty liver disease and metabolic dysfunction–associated steatohepatitis highlighted dysregulated amino acid metabolism as a common metabolic abnormality. Conclusions: Our comprehensive multiomic analyses reveal new insights into the fundamental biology and pathogenesis mechanisms of human FALD.

27 December 2024 in Journal of Orthopaedic Research
Verified
Journal Article
Open access
MTMargaret K. Tamburro
Margaret K. Tamburro
KBKelsey A. Bonilla
Kelsey A. Bonilla
SSSnehal S. Shetye
Snehal S. Shetye
TLThomas P. Leahy
Thomas P. Leahy
JEJeremy D. Eekhoff
Jeremy D. Eekhoff
LSLouis J Soslowsky
Louis J Soslowsky
Exercise influences clinical Achilles tendon health in humans, but animal models of exercise‐related Achilles tendon changes are lacking. Moreover, previous investigations of the effects of treadmill running exercise on rat Achilles tendon demonstrate variable outcomes. Our objective was to assess the functional, structural, cellular, and biomechanical impacts of treadmill running exercise on rat Achilles tendon with sensitive in and ex vivo approaches. Three running levels were assessed over the course of 8 weeks: control (cage activity), moderate‐speed (treadmill running at 10 m/min, no incline), and high‐speed (treadmill running at 20 m/min, 10° incline). We hypothesized that moderate‐speed treadmill running would beneficially impact tendon biomechanics through increased tenocyte cellularity, metabolism, and anabolism whereas high‐speed treadmill running would cause a tendinopathic phenotype with compromised tendon biomechanics due to pathologic tenocyte differentiation, metabolism, and catabolism. Contrary to our hypothesis, treadmill running exercise at these speeds had a nominal effect on the rat Achilles tendon. Treadmill running modestly influenced tenocyte metabolism and nuclear aspect ratio as well as viscoelastic tendon properties but did not cause a tendinopathic phenotype. These findings highlight the need for improved models of exercise‐ and loading‐related tendon changes that can be leveraged to develop strategies for tendinopathy prevention and treatment.

25 July 2024 in medRxiv
Verified
Preprint
Open access
PDF file
FNFawaz Naeem
Fawaz Naeem
TLTeresa C. Leone
Teresa C. Leone
CPChristopher Petucci
Christopher Petucci
CSClarissa Shoffler
Clarissa Shoffler
RKRavindra C. Kodihalli
Ravindra C. Kodihalli
DKDaniel P. Kelly
Daniel P. Kelly
Background Two general phenotypes of heart failure (HF) are recognized: HF with reduced ejection fraction (HFrEF) and with preserved EF (HFpEF). To develop HF disease phenotype-specific approaches to define and guide treatment, distinguishing biomarkers are needed. The goal of this study was to utilize quantitative metabolomics on a large, diverse population to replicate and extend existing knowledge of the plasma metabolic signatures in human HF. Methods Quantitative, targeted LC/MS plasma metabolomics was conducted on 787 samples collected by the Penn Medicine BioBank from subjects with HFrEF (n=219), HFpEF (n=357), and matched non-failing Controls (n=211). A total of 90 metabolites were analyzed, comprising 28 amino acids, 8 organic acids, and 54 acylcarnitines. 733 of these samples were also processed via an OLINK protein panel for proteomic profiling. Results Consistent with previous studies, unsaturated forms of medium/long chain acylcarnitines were elevated in the HFrEF group to a greater extent than the HFpEF group compared to Controls. A number of amino acid derivatives, including 1- and 3-methylhistidine, homocitrulline, and symmetric (SDMA) and asymmetric (ADMA) dimethylarginine were elevated in HF, with ADMA elevated uniquely in HFpEF. Plasma branched-chain amino acids (BCAA) were not different across the groups; however, short-chain acylcarnitine species indicative of BCAA catabolism were significantly elevated in both HF groups. The ketone body 3-hydroxybutyrate (3-HBA) and its metabolite C4-OH carnitine were uniquely elevated in the HFrEF group. Linear regression models demonstrated a significant correlation between plasma 3-HBA and NT-proBNP in both forms of HF, stronger in HFrEF. Conclusions These results identify plasma signatures that are shared as well as potentially distinguish between HFrEF and HFpEF. Metabolite markers for ketogenic metabolic re-programming in extra-cardiac tissues were identified as unique signatures in the HFrEF group, possibly related to the lipolytic action of increased levels of BNP. Future studies will be necessary to further validate these metabolites as HF biosignatures that may guide phenotype-specific therapeutics and provide insight into the systemic metabolic responses to HFpEF and HFrEF. What Is New? “Real world” targeted metabolomic profiling on wide range of metabolites in a diverse population of patients with HFrEF and HFpEF. Levels of 3-hydroxybutyrate and its metabolite C4OH-carnitine were uniquely increased in the HFrEF group and correlated with levels of plasma NT-proBNP in both the heart failure groups, indicating the possibility of a heart-adipose-liver axis. Asymmetric dimethylarginine, a known inhibitor of nitric oxide synthase, was uniquely upregulated in HFpEF suggesting that there may also be an underlying component of vascular dysregulation contributing to HFpEF pathophysiology. What Are the Clinical Implications? The plasma metabolomic changes seen in the heart failure cohorts support the existing theory of metabolic reprogramming, providing further rationale for the pursuit of therapeutic targets for the treatment of heart failure. Quantitative metabolomic profiling shows promise for guiding therapeutic decisions in HFrEF and HFpEF. Modulation of natriuretic peptides may enhance the delivery of ketone and fatty acids to the “fuel starved” failing heart.

2 June 2026 in bioRxiv
Verified
Preprint
Open access
MRMalihe Rezaee
Malihe Rezaee
MKMohammad Keykhaei
Mohammad Keykhaei
NKNavid Koleini
Navid Koleini
TPTegbir Panesar
Tegbir Panesar
SLSimiao Li
Simiao Li
DKDavid A. Kass
David A. Kass
Background: Impaired myocardial metabolism is a defining feature of heart failure, but many defective pathways and mechanisms remain to be identified. Prior studies find phosphoglycerate kinase and its synthesized product 3-phospho-glycerate required for the serine synthetic pathway (SSP) are reduced in human HFpEF myocardium. As serine is also provided exogenously, the impact of SSP reduction is uncertain. Here, we tested if and how SSP decline coupled to phosphoglycerate dehydrogenase (PHGDH) impacts cardiomyocyte (CM) and whole heart metabolic remodeling and stress responses. Methods: Studies were performed in isolated CMs and mice with CM-selective knock-down of PHGDH. Using pharmacological inhibition or genetic silencing of PHGDH, we tested their impact on CM one-carbon metabolism pathways, cell hypertrophic responses, mitochondrial respiration, and in vivo functional, structural, and metabolic adaptations to pressure-overload stress. Results: In CMs, PHGDH inhibition caused dose-dependent serine depletion linearly coupled with cytotoxicity, accompanied by NAD/NADH and GSH/GSSG imbalance, reduced ATP, and disruption of one-carbon and nucleotide metabolites. Stable-isotope tracing revealed distinct metabolic fates of glucose-derived (SSP) versus exogenous serine. Exogenous serine did not rescue PHGDH-deficient CMs, whereas combined ribose and an anti-oxidant (DTT) attenuated injury and reduced nucleotide pools. PHGDH suppression reduced amino acid abundance, impaired nascent protein synthesis, and blunted endothelin-1–induced hypertrophic and mitochondrial respiration. In vivo , cardiomyocyte-specific PHGDH heterozygous mice (PHGDH +/− ) had no basal phenotype, but amplified chamber dilation, dysfunction, fibrosis, and mortality 4 weeks after transverse aortic constriction (TAC). Corresponding increases in amino acids, one-carbon metabolites, nucleotides, and TCA-cycle intermediates in wild-type TAC hearts were significantly blunted in PHGDH +/− hearts. Conclusions: Cardiomyocyte SSP is a critical regulator of redox balance, one-carbon metabolism, purine synthesis, amino acid homeostasis, and growth-related pathways required for cardiac adaptation to pressure overload. It is non-redundant with exogenous serine by providing distinct influences on key metabolic pathways and is a potential therapeutic target.